H7N9 shows resistance to Roche's Tamiflu

The H7N9 strain of bird flu has shown resistance to Roche's ($RHHBY) antiviral Tamiflu for the first time. In a study of 14 patients, Tamiflu failed to reduce the amount of virus found on throat swabs in three people. Resistance could limit the effectiveness of the main line of defense until a vaccine is developed. News

Suggested Articles

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

The partnership aims to make the production of vaccines that use adenovirus as vectors more cost-effective and contamination-free.

GSK's Shingrix has nabbed a huge chunk of the U.S. shingles-shot market, just five months after it was approved by the FDA.